Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04948827
Other study ID # SBP-9330-101
Secondary ID U01DA051077
Status Completed
Phase Phase 1
First received
Last updated
Start date July 20, 2021
Est. completion date March 6, 2023

Study information

Verified date March 2024
Source Camino Pharma, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single center, first-in-human, randomized, double-blind, placebo-controlled, Single-Ascending Dose (SAD) / Multiple-Ascending Dose (MAD) study incorporating a food-effect cohort.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date March 6, 2023
Est. primary completion date March 6, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Provision of written informed consent prior to the initiation of any protocol-specific procedures 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Healthy male or female subject = 18 and = 55 years of age 4. Body mass index (BMI) = 18.5 kg/m2 and = 32.0 kg/m2 5. Body weight = 50.0 kg at Screening 6. A female subject must meet at least one of the following criteria: a. Is of childbearing potential and agrees to use an acceptable contraceptive method. b. Is of non-childbearing potential, defined as surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or is in a postmenopausal state (i.e., at least 1 year without menses prior to the first study drug administration without an alternative medical condition and confirmed with a serum follicle-stimulating hormone [FSH] > 40 IU/L at Screening) 7. Male subjects, if not surgically sterilized, must agree to use adequate contraception and not donate sperm from the first admission to the CRU until 90 days after the last study drug administration. 8. Part A and B only: Never- or nonsmoker (a nonsmoker is defined as someone who completely stopped using nicotine products for at least 2 years prior to the first study drug administration) 9. Have no clinically significant medical or mental health conditions captured in the medical history or evidence of clinically significant findings on the physical examination and/or ECG, as determined by an Investigator 10. No clinically significant abnormalities in blood pressure, heart rate, body temperature and respiratory rate and no evidence of orthostatic hypotension or postural tachycardia at Screening. Part C Only: 11. Are current tobacco cigarette smokers who smoke an average of 10 or more cigarettes per day in the 30 days prior to Screening 12. Expired breath CO level =10 parts per million (ppm) at Screening and prior to the first study drug administration 13. Positive test result for cotinine at Screening and prior to the first study drug administration 14. Are not motivated to try to quit smoking from Screening through 30 days from the first study drug administration Exclusion Criteria: 1. Female who is lactating 2. Female who is pregnant according to the pregnancy test at Screening or prior to the first study drug administration 3. Female who is planning to become pregnant during this study or within 90 days after the last study drug administration 4. Male with female partner who is pregnant, lactating, or planning to become pregnant during this study or within 90 days after the last study drug administration 5. Poor venous access as determined by an Investigator at Screening 6. History of significant hypersensitivity to SBP-9330 or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs 7. Presence of any medical condition that, in the opinion of an Investigator, poses an unacceptable risk to the subjects 8. Presence or history of significant gastrointestinal, liver or kidney disease, or surgery that may affect drug absorption 9. Evidence or history of clinically significant cardiovascular, pulmonary, hematologic, psychiatric (including mood and substance use disorders), neurological (including migraines, seizures, and epilepsy), endocrine, renal, hepatic, gastrointestinal, immunologic or dermatologic disease 10. History of malignancy within the past five years, except for successfully treated basal cell carcinoma of the skin 11. History of suicidal ideation or suicidal behavior as per the C-SSRS questionnaire administered at Screening 12. Evidence or history of significant psychiatric disease or any DSM-5 disorder as assessed by the Mini International Neuropsychiatric Interview (M.I.N.I.) administered at Screening 13. Routine or chronic use of more than three grams of acetaminophen daily 14. Strenuous activity, sunbathing, and contact sports within 48 hours prior to (first) admission to the CRU 15. Current alcohol consumption exceeding two standard drinks per day on average (1 standard drink=10 grams of alcohol) for male subjects and one standard drink per day on average for female subjects 16. History of alcohol or drug (other than caffeine) use disorder within 12 months prior to Screening 17. Any clinically significant illness in the 28 days prior to the first study drug administration 18. QTcF interval (QT interval corrected for heart rate according to Fridericia) > 450 ms for males and > 470 ms for females at Screening or on Day -1 19. Parts A and B only: Positive test result for alcohol and/or drugs of abuse at Screening or prior to the first drug administration 20. Positive test results for HIV-1/HIV-2 antibodies, hepatitis B surface antigen or hepatitis C antibody 21. Consumption of any prescription drugs (with the exception of hormonal contraceptives or hormone replacement therapy) or over-the-counter medications and nutrients known to modulate cytochrome P450 (CYP450) enzymes activity (e.g., grapefruit or grapefruit juice, pomelo juice, star fruit, or Seville [blood] orange products) or St. John's Wort within 14 days prior to the first study drug administration 22. Consumption of other prescription and over-the-counter medication not specifically excluded by Exclusion Criterion 21 including health supplements and herbal remedies within 7 days prior to the first study drug administration (an exception is made for paracetamol [acetaminophen], which is allowed up to admission to the clinic). 23. Any other clinically significant abnormalities in laboratory test results at Screening that would, in the opinion of an Investigator, increase the subject's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data 24. Intake of an investigational product in the 30 days or 5 half-lives (whichever is longer) prior to Screening 25. Inclusion in a previous cohort of this clinical study 26. Employee of the contract research organization (CRO) or the Sponsor. 27. Blood donation (excluding plasma donation) of approximately 500 mL within 56 days prior to Screening 28. Plasma donation within 7 days prior to Screening Part C Only: 29. History of generalized rash reaction to any drugs 30. Positive test result (except cotinine) for alcohol and/or drugs of abuse at Screening or prior to the first study drug administration 31. Use of smoking cessation aids (NRT, bupropion, or varenicline) within 30 days prior to the first study drug administration 32. Unable to abstain from smoking tobacco cigarettes for at least 1 hour before and 2 hours after study drug administration 33. Unable to abstain from using nicotine-containing products other than tobacco cigarettes (e.g., pipes, cigars, e-cigarettes or vapes, nicotine topical patches, nicotine gum, or nicotine lozenges) during the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SBP-9330
SBP-9330 oral capsules
Placebo
Placebo oral capsules

Locations

Country Name City State
United States Altasciences Clinical Kansas, Inc Overland Park Kansas

Sponsors (4)

Lead Sponsor Collaborator
Camino Pharma, LLC National Institute on Drug Abuse (NIDA), Sanford Burnham Prebys Medical Discovery Institute, University of California, San Diego

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Expired Carbon Monoxide (ECO) Level Expired breath CO was measured with a Bedfont Smokerlyzer™ Daily from Screening through Day 14
Other Plasma Cotinine Level Blood samples were collected to measure plasma cotinine levels Predose, Day 7 and Day 14
Other Number of Cigarettes Smoked A daily smoking log was kept to document the number of cigarettes smoked Daily from Screening through Day 14
Other Minnesota Nicotine Withdrawal Scale (MNWS) A self-report measure used to monitor symptoms of tobacco withdrawal. Screening through Day 14
Other Questionnaire on Smoking Urges - Brief Version (QSU-Brief) A self-report questionnaire used to measure cravings to smoke. Screening through Day 15
Primary Number of Treatment-Emergent Adverse Events [Safety and Tolerability] Number of drug-related adverse events as determined by clinically significant changes in vital signs, physical examination findings, ECG parameters, C-SSRS questionnaire results, and clinical laboratory results Part A: 8 days Part B: 21 days Part C: 21 days
Secondary Pharmacokinetics of SBP-9330: Cmax Maximum observed concentration (Cmax) PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary Pharmacokinetics of SBP-9330: Tmax Time to reach maximum observed concentration (Tmax) PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary Pharmacokinetics of SBP-9330: AUC 0-24 Area under the concentration time curve from time 0 (dose administration) to 24 hours PK samples were obtained at selected timepoints from pre-dose until 24 hours post-dose
Secondary Pharmacokinetics of SBP-9330: AUC 0-T Area under the concentration time curve from time 0 (dose administration) to the time of last quantifiable concentration PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary Pharmacokinetics of SBP-9330: AUC 0-8 Area under the concentration time curve extrapolated to infinity PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary Pharmacokinetics of SBP-9330: T½ Terminal elimination half-life PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary Pharmacokinetics of SBP-9330: CL/F Apparent total clearance PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary Pharmacokinetics of SBP-9330: Vz/F Apparent volume of distribution PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary Pharmacokinetics of SBP-9330: C Trough Observed concentration at the end of the dosing interval PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary Pharmacokinetics of SBP-9330: Ct Concentration at the end of the dosing interval. PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary Pharmacokinetics of SBP-9330: AUCt Area under the concentration time curve over the dosing interval at steady state, calculated from 0 to 24 hours (dosing interval) PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary Pharmacokinetics of SBP-9330: T½, Eff Effective half-life PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary Pharmacokinetics of SBP-9330: CL/Fss Apparent total clearance at steady state PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary Pharmacokinetics of SBP-9330: Vz/Fss Apparent volume of distribution at steady state PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary Pharmacokinetics of SBP-9330: RAC(Cmax) Accumulation ratio evaluated by comparing Day 14 Cmax to Day 1 Cmax PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Secondary Pharmacokinetics of SBP-9330: RAC(AUC) Accumulation ratio evaluated by comparing Day 14 AUCt to Day 1 AUC0-24 PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
See also
  Status Clinical Trial Phase
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04617444 - The ESTxENDS Trial- Substudy on Effects of Using Electronic Nicotine Delivery Systems (ENDS) on Olfactory Function N/A
Completed NCT02796391 - Facilitating Smoking Cessation With Reduced Nicotine Cigarettes Phase 2
Completed NCT03397511 - Incorporating Financial Incentives to Increase Smoking Cessation Among Asian Americans Residing in New York City N/A
Not yet recruiting NCT05188287 - A Culturally Tailored Smartphone Application for African American Smokers N/A
Recruiting NCT05264428 - The Effect of Honey on Lessening the Withdrawal Symptoms N/A
Recruiting NCT05846841 - Personalized Tobacco Treatment in Primary Care (MOTIVATE) N/A
Completed NCT04133064 - Assessment of the Pivot Breath Sensor: Single-Arm Cohort Study N/A
Completed NCT03187730 - Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants Phase 4
Completed NCT03474783 - To Explore the Factors Affecting the Effectiveness of Smoking Cessation N/A
Completed NCT04635358 - Feasibility Study of Smoking Cessation for the Staff of a Hospital Center N/A
Terminated NCT03670264 - BE Smokefree: Behavioral Economics Incentives to Engage Adolescents in Smoking Cessation N/A
Not yet recruiting NCT06307496 - VIDeOS for Smoking Cessation N/A
Completed NCT02997657 - Positive Psychotherapy for Smoking Cessation Enhanced With Text Messaging: A Randomized Controlled Trial N/A
Completed NCT02905656 - Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit N/A
Completed NCT03206619 - A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
Completed NCT02562521 - A Smoking Cessation Intervention for Yale Dining Employees Phase 4
Completed NCT02239770 - Pharmacokinetics of Nicotine Film in Smokers N/A
Recruiting NCT02422914 - Benefits of Tobacco Free Cigarette N/A